INBX
Inhibrx Biosciences Inc. · Healthcare · Biotechnology
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q1 2025
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 70 | +7 | 8.53M | $807.74M | +12 | −4 |
| Q1 2026 | 65 | -3 | 7.61M | $511.38M | +3 | −7 |
| Q4 2025 | 69 | 0 | 8.07M | $637.42M | +2 | −1 |
| Q3 2025 | 17 | +7 | 4.45M | $150.05M | +7 | n/a |
| Q2 2025 | 7 | 0 | 3.86M | $55.09M | n/a | n/a |
| Q1 2025 | 4 | -1 | 2.48M | $34.64M | n/a | −1 |
| Q4 2024 | 5 | -2 | 2.53M | $38.98M | n/a | −2 |
| Q3 2024 | 6 | +1 | 2.46M | $38.48M | +2 | −1 |
| Q2 2024 | 5 | n/a | 2.53M | $35.86M | n/a | n/a |
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 1.79M | 0.0% | $25.01M | 0.1% | Held | 4 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 260.03K | +1.9% | $3.64M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Millennium Management ✦ | 255.34K | -1.2% | $3.57M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | State Street Global Advisors ✦ (被动) | 172.90K | -2.0% | $2.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| Marshall Wace | $825,224 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 134 持有人, 12.71M 股份, $853.40M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
Officer, Director · Chief Executive… · 2.47K 股 @ 84.07 · $207,655
Officer, Director · Chief Executive… · 100 股 @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.45K 股 @ 85.00 · $208,333
Officer, Director · Chief Executive… · 2.45K 股 @ 84.07 · $205,889
Officer, Director · Chief Executive… · 100 股 @ 85.76 · $8,576
Officer, Director · Chief Executive… · 2.47K 股 @ 85.00 · $209,948
Officer, Director · Chief Executive… · 3.00K 股 @ 101.70 · $305,106
Officer, Director · Chief Executive… · 1.50K 股 @ 98.88 · $148,320
Officer, Director · Chief Executive… · 2.18K 股 @ 99.60 · $216,727
Officer, Director · Chief Executive… · 3.32K 股 @ 98.87 · $328,630
公开市场卖出 (S)
Director · 500 股 · $52,525
Director · 500 股 · $55,130
Director · 500 股 · $55,888
Director · 500 股 · $57,898
Director · 500 股 · $57,570
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论